MX2023007578A - Uso del compuesto profarmaco antagonista nk1 en combinacion con un antagonista del receptor 5-ht3. - Google Patents

Uso del compuesto profarmaco antagonista nk1 en combinacion con un antagonista del receptor 5-ht3.

Info

Publication number
MX2023007578A
MX2023007578A MX2023007578A MX2023007578A MX2023007578A MX 2023007578 A MX2023007578 A MX 2023007578A MX 2023007578 A MX2023007578 A MX 2023007578A MX 2023007578 A MX2023007578 A MX 2023007578A MX 2023007578 A MX2023007578 A MX 2023007578A
Authority
MX
Mexico
Prior art keywords
antagonist
combination
receptor antagonist
prodrug compound
receptor
Prior art date
Application number
MX2023007578A
Other languages
English (en)
Inventor
Lianshan Zhang
Jian Huang
Changyong Yang
Cheng Liao
Daping Xu
Original Assignee
Shanghai Shengdi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Shengdi Pharmaceutical Co Ltd filed Critical Shanghai Shengdi Pharmaceutical Co Ltd
Publication of MX2023007578A publication Critical patent/MX2023007578A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere al uso de un compuesto profármaco antagonista NK1 y un antagonista del receptor 5-HT3. En particular, la presente invención se refiere al uso de un compuesto representado por la fórmula (I) o una sal farmacéuticamente aceptable del mismo en combinación con un antagonista del receptor 5-HT3 en la preparación de un fármaco para prevenir o tratar las náuseas y/o los vómitos. (ver Fórmula).
MX2023007578A 2020-12-25 2021-12-24 Uso del compuesto profarmaco antagonista nk1 en combinacion con un antagonista del receptor 5-ht3. MX2023007578A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011559059 2020-12-25
CN202111066727 2021-09-13
PCT/CN2021/141009 WO2022135549A1 (zh) 2020-12-25 2021-12-24 Nk1拮抗剂前药化合物与5-ht3受体拮抗剂的联用用途

Publications (1)

Publication Number Publication Date
MX2023007578A true MX2023007578A (es) 2023-07-06

Family

ID=82157418

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007578A MX2023007578A (es) 2020-12-25 2021-12-24 Uso del compuesto profarmaco antagonista nk1 en combinacion con un antagonista del receptor 5-ht3.

Country Status (10)

Country Link
US (1) US20240016822A1 (es)
EP (1) EP4268818A1 (es)
JP (1) JP2024501994A (es)
KR (1) KR20230127252A (es)
CN (1) CN116472048A (es)
AU (1) AU2021407138A1 (es)
CA (1) CA3203188A1 (es)
MX (1) MX2023007578A (es)
TW (1) TW202233175A (es)
WO (1) WO2022135549A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE188472T1 (de) 1992-10-28 2000-01-15 Merck Sharp & Dohme 4-arylmethyloxymethyl piperidine als tachykinin antagonisten
JPH08504435A (ja) 1992-12-14 1996-05-14 メルク シヤープ エンド ドーム リミテツド タキキニン受容体拮抗剤としての４−アミノメチル／チオメチル／スルホニルメチル−４−フェニルピペリジン
AU685212B2 (en) 1994-01-13 1998-01-15 Merck Sharp & Dohme Limited Gem-disubstituted azacyclic tachykinin antagonists
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
CA2550432A1 (en) * 2003-12-22 2005-07-14 Schering Corporation Pharmaceutical compositions
EP3143996A1 (en) 2009-08-14 2017-03-22 OPKO Health, Inc. Intravenous formulations of neurokinin 1-antagonists
BR112021026554A2 (pt) * 2019-06-28 2022-05-24 Jiangsu Hengrui Medicine Co Antagonista de neurocinina-1

Also Published As

Publication number Publication date
CA3203188A1 (en) 2022-06-30
EP4268818A1 (en) 2023-11-01
AU2021407138A1 (en) 2023-06-29
WO2022135549A1 (zh) 2022-06-30
KR20230127252A (ko) 2023-08-31
JP2024501994A (ja) 2024-01-17
US20240016822A1 (en) 2024-01-18
TW202233175A (zh) 2022-09-01
CN116472048A (zh) 2023-07-21

Similar Documents

Publication Publication Date Title
JOP20220101A1 (ar) مثبطات صغيرة الجزئ لطافر G12C لبروتين ساركوما جرذان Kirsten (KRAS)
CR20220281A (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
MX2022015207A (es) Compuestos antivirales para tratar infecciones por coronavirus, picornavirus, y norovirus.
PH12017501326A1 (en) Tgf-� inhibitors
SG10201407538WA (en) Intravenous formulations of neurokinin-1 antagonists
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
MX2021016085A (es) Derivados de benzisoxazol sulfonamida.
MX370608B (es) Compuestos de morfinano.
TW200626574A (en) HIV inhibiting 5-heterocyclyl pyrimidines
NZ589764A (en) NMDA receptor antagonists for the treatment of neuropsychiatric disorders
TNSN07016A1 (en) Indole-2-carboxamidine derivatives as nmda receptor antagonists
ATE530182T1 (de) Pharmazeutische zubereitungen enthaltend nk1- rezeptoren antagonisten und natriumkanal blockierende verbindungen
MX2012001160A (es) Agonistas del receptor de esfingosina-1-fosfato.
MX2018006225A (es) Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash).
MX2021015827A (es) Antagonista de neurokinin -1.
MX2021015654A (es) Antagonista del receptor 2 de prostaglandina e2 (ep2).
MX2023007579A (es) Derivado de borato y usos del mismo.
CR20210014A (es) Derivados de pirrolo [1,2-b] piridazina
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
MX2023007578A (es) Uso del compuesto profarmaco antagonista nk1 en combinacion con un antagonista del receptor 5-ht3.
MX2022005766A (es) Compuestos y métodos para la preparación de compuestos moduladores de esfingosina 1-fosfato tipo 1 (s1p1).
JOP20200127A1 (ar) مشتقات بيريدينون واستخدامها كمثبطات alk-2 انتقائية
JOP20220329A1 (ar) مضاد مستقبل crf1 لعلاج فرط تنسج الكظر الخلقي
MX2021014458A (es) Compuestos triciclicos.